---
id: "question-ai-ip-governance"
type: "open-question"
source_timestamps: ["§ 3. Use strategic partnerships to unlock the value of AI in drug discovery and development.", "¶15"]
tags: ["governance", "intellectual-property"]
related: ["action-establish-ai-governance"]
resolutionPath: "Publication of standardized, open-source legal and data-sharing templates endorsed by bodies like the AMA, designed specifically for AMC-AI startup partnerships."
sources: ["tail2"]
sourceVaultSlug: "hbr-seg-tail2"
originDay: 2
articleStem: "hbr-tail-131-medical-drug-discovery"
sourceUrl: "https://hbr.org/2026/04/u-s-medical-centers-need-a-new-model-for-drug-discovery-and-development"
sourceTitle: "U.S. Medical Centers Need a New Model for Drug Discovery and Development"
---
# Effective AI Governance Frameworks

The text advises establishing **"thoughtful governance frameworks"** ([[action-establish-ai-governance]]) to handle **long-term dependence, data privacy, and IP** when partnering with external AI firms — but it **does not detail which specific contractual or technical mechanisms actually succeed** in protecting AMC interests in these highly **asymmetrical** tech partnerships.

**Resolution path:** publication of **standardized, open-source legal and data-sharing templates**, endorsed by bodies like the AMA, purpose-built for AMC–AI-startup partnerships.